LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the polymyositis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat polymyositis.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Polymyositis: Market overview
Polymyositis is a disease characterized by chronic muscle inflammation accompanied by muscle weakness. Polymyositis affects skeletal muscles. The symptoms of polymyositis include muscle weakness, aching or painful muscles, shortness of breath, and difficulty in swallowing and speaking, and heart arrhythmias. The symptoms of the disease can be treated with corticosteroids, immunosuppressant, drugs such as azathioprine and methotrexate, and immunoglobulins.
According to a senior market research analyst at Technavio, “Polymyositis mostly affects adults in the age group of 31-60 years and is rarely seen in people under 18 years of age. As per a data published by the Committee for Orphan Medicinal Products, polymyositis affected approximately 0.4 people in 10,000 people in the EU region.”
Polymyositis: Segmentation analysis
This pipeline analysis report segments the polymyositis market based on therapies employed (monotherapy and combination therapy), RoA (subcutaneous, and intravenous), therapeutic modality (monoclonal antibody, fusion protein, and small molecule), targets (interleukin-6 receptor, T cells, plasmacytoid dendritic cells, and NF-kB), MoA (interleukin-6 receptor antagonist, T cells activation inhibitor, plasmacytoid dendritic cells modulator, and NF-kB inhibitor), geographical segmentation (US, and others) and recruitment status (completed, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, around 50% of the molecules that are being investigated for the treatment of polymyositis are monoclonal antibody.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
